ABSTRACT
Magnetic resonance imaging (MRI) of the liver is undergoing a transition from a problem-solving imaging modality to a first-line imaging modality for many hepatic diseases. High soft tissue resolution, the absence of ionizing radiation, and multiparametric imaging capability, together with technological advances in MRI and the availability of function-specific contrast agents, form the foundation of this transition and position MRI as the gold standard in the evaluation of liver pathologies.
Keywords:
Liver MRI, diffusion weighted imaging, ADC, hepatocellular contrast agent, MR elastography
References
1
Moon AM, Singal AG, Tapper EB. Contemporary epidemiology of chronic liver disease and cirrhosis. Clin Gastroenterol Hepatol. 2020; 18: 2650-66.
2
Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023; 79: 1542-56.
3
Abboud Y, Ismail M, Khan H, Medina-Morales E, Alsakarneh S, Jaber F, et al. Hepatocellular carcinoma incidence and mortality in the usa by sex, age, and race: a nationwide analysis of two decades. J Clin Transl Hepatol. 2024; 12: 172-81.
4
Jiang H, Chen HC, Lafata KJ, Bashir MR. Week 4 liver fat reduction on MRI as an early predictor of treatment response in participants with nonalcoholic steatohepatitis. Radiology. 2021; 300: 361-8.
5
Thomaides-Brears HB, Lepe R, Banerjee R, Duncker C. Multiparametric MR mapping in clinical decision-making for diffuse liver disease. Abdom Radiol (NY). 2020; 45: 3507-22.
6
Herborn CU, Vogt F, Lauenstein TC, Goyen M, Debatin JF, Ruehm SG. MRI of the liver: can True FISP replace HASTE? J Magn Reson Imaging. 2003; 17: 190-6.
7
Shetty AS, Fraum TJ, Ludwig DR, Hoegger MJ, Zulfiqar M, Ballard DH, et al. Body MRI: imaging protocols, techniques, and lessons learned. Radiographics. 2022; 42: 2054-74.
8
Markl M, Leupold J. Gradient echo imaging. J Magn Reson Imaging. 2012; 35: 1274-89.
9
Ramalho M, Altun E, Herédia V, Zapparoli M, Semelka R. Liver MR imaging: 1.5T versus 3T. Magn Reson Imaging Clin N Am. 2007; 15: 321-47.
10
Fowler KJ, Brown JJ, Narra VR. Magnetic resonance imaging of focal liver lesions: approach to imaging diagnosis. Hepatology. 2011; 54: 2227-37.
11
Watanabe A, Ramalho M, AlObaidy M, Kim HJ, Velloni FG, Semelka RC. Magnetic resonance imaging of the cirrhotic liver: an update. World J Hepatol. 2015; 7: 468-87.
12
Albiin N. MRI of focal liver lesions. Curr Med Imaging Rev. 2012; 8: 107-16.
13
Agostini A, Kircher MF, Do RK, Borgheresi A, Monti S, Giovagnoni A, et al. Magnetic resonanance imaging of the liver (including biliary contrast agents)-part 2: protocols for liver magnetic resonanance imaging and characterization of common focal liver lesions. Semin Roentgenol. 2016; 51: 317-33.
14
Chandarana H, Feng L, Ream J, Wang A, Babb JS, Block KT, et al. Respiratory motion-resolved compressed sensing reconstruction of free-breathing radial acquisition for dynamic liver magnetic resonance imaging. Invest Radiol. 2015; 50: 749-56.
15
Hood MN, Ho VB, Smirniotopoulos JG, Szumowski J. Chemical shift: the artifact and clinical tool revisited. Radiographics. 1999; 19: 357-71.
16
Goncalves Neto JA, Altun E, Vaidean G, Elazzazi M, Troy J, Ramachandran S, et al. Early contrast enhancement of the liver: exact description of subphases using MRI. Magn Reson Imaging. 2009; 27: 792-800.
17
Guglielmo FF, Mitchell DG, Roth CG, Deshmukh S. Hepatic MR imaging techniques, optimization, and artifacts. Magn Reson Imaging Clin N Am. 2014; 22: 263-82.
18
Wile GE, Leyendecker JR. Magnetic resonance imaging of the liver: sequence optimization and artifacts. Magn Reson Imaging Clin N Am. 2010; 18: 525-47.
19
Gandhi SN, Brown MA, Wong JG, Aguirre DA, Sirlin CB. MR contrast agents for liver imaging: what, when, how. Radiographics. 2006; 26: 1621-36.
20
Sharma P, Kalb B, Kitajima HD, Salman KN, Burrow B, Ray GL, et al. Optimization of single injection liver arterial phase gadolinium enhanced MRI using bolus track real-time imaging. J Magn Reson Imaging. 2011; 33: 110-8.
21
Cogley JR, Miller FH. MR imaging of benign focal liver lesions. Radiol Clin North Am. 2014; 52: 657-82.
22
Jhaveri KS, Hosseini-Nik H. MRI of cholangiocarcinoma. J Magn Reson Imaging. 2015; 42: 1165-79.
23
Tanimoto A, Lee JM, Murakami T, Huppertz A, Kudo M, Grazioli L. Consensus report of the 2nd forum for liver MRI. Eur Radiol. 2009; 19(Suppl 5): S975-89.
24
Matos AP, Velloni F, Ramalho M, AlObaidy M, Rajapaksha A, Semelka RC. Focal liver lesions: practical magnetic resonance imaging approach. World J Hepatol. 2015; 7: 1987-2008.
25
Thomaides-Brears HB, Lepe R, Banerjee R, Duncker C. Multiparametric MR mapping in clinical decision-making for diffuse liver disease. Abdom Radiol (NY). 2020; 45: 3507-22.
26
Neri E, Bali MA, Ba-Ssalamah A, Boraschi P, Brancatelli G, Alves FC, et al. ESGAR consensus statement on liver MR imaging and clinical use of liver-specific contrast agents. Eur Radiol. 2016; 26: 921-31.
27
Wang C, Yuan XD, Wu N, Sun WR, Tian Y. Optimization of hepatobiliary phase imaging in gadoxetic acid-enhanced magnetic resonance imaging: a narrative review. Quant Imaging Med Surg. 2023; 13: 1972-82.
28
Schalkx HJ, van Stralen M, Coenegrachts K, van den Bosch MA, van Kessel CS, van Hillegersberg R, et al. Liver perfusion in dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI): comparison of enhancement in Gd-BT-DO3A and Gd-EOB-DTPA in normal liver parenchyma. Eur Radiol. 2014; 24: 2146-56.
29
Bashir MR. Magnetic resonance contrast agents for liver imaging. Magn Reson Imaging Clin N Am. 2014; 22: 283-93.
30
Haradome H, Grazioli L, Tsunoo M, Tinti R, Frittoli B, Gambarini S, et al. Can MR fluoroscopic triggering technique and slow rate injection provide appropriate arterial phase images with reducing artifacts on gadoxetic acid-DTPA (Gd-EOB-DTPA)-enhanced hepatic MR imaging? J Magn Reson Imaging. 2010; 32: 334-40.
31
Pietryga JA, Burke LM, Marin D, Jaffe TA, Bashir MR. Respiratory motion artifact affecting hepatic arterial phase imaging with gadoxetate disodium: examination recovery with a multiple arterial phase acquisition. Radiology. 2014; 271: 426-34.
32
Guglielmo FF, Mitchell DG, Gupta S. Gadolinium contrast agent selection and optimal use for body MR imaging. Radiol Clin North Am. 2014; 52: 637-56.
33
Grazioli L, Morana G, Kirchin MA, Schneider G. Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study. Radiology. 2005; 236: 166-77.
34
Suh CH, Kim KW, Kim GY, Shin YM, Kim PN, Park SH. The diagnostic value of Gd-EOB-DTPA-MRI for the diagnosis of focal nodular hyperplasia: a systematic review and meta-analysis. Eur Radiol. 2015; 25: 950-60.
35
Grazioli L, Bondioni MP, Faccioli N, Gambarini S, Tinti R, Schneider G, et al. Solid focal liver lesions: dynamic and late enhancement patterns with the dual phase contrast agent gadobenate dimeglumine. J Gastrointest Cancer. 2010; 41: 221-32.
36
Grazioli L, Bondioni MP, Haradome H, Motosugi U, Tinti R, Frittoli B, et al. Hepatocellular adenoma and focal nodular hyperplasia: value of gadoxetic acid-enhanced MR imaging in differential diagnosis. Radiology. 2012; 262: 520-9.
37
Choi JY, Lee JM, Sirlin CB. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects. Radiology. 2014; 272: 635-54.
38
Sano K, Ichikawa T, Motosugi U, Sou H, Muhi AM, Matsuda M, et al. Imaging study of early hepatocellular carcinoma: usefulness of gadoxetic acid-enhanced MR imaging. Radiology. 2011; 261: 834-44.
39
Choi JY, Lee JM, Sirlin CB. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part II. Extracellular agents, hepatobiliary agents, and ancillary imaging features. Radiology. 2014; 273: 30-50.
40
Tsuboyama T, Onishi H, Kim T, Akita H, Hori M, Tatsumi M, et al. Hepatocellular carcinoma: hepatocyte-selective enhancement at gadoxetic acid-enhanced MR imaging--correlation with expression of sinusoidal and canalicular transporters and bile accumulation. Radiology. 2010; 255: 824-33.
41
Vilgrain V, Van Beers BE, Pastor CM. Insights into the diagnosis of hepatocellular carcinomas with hepatobiliary MRI. J Hepatol. 2016; 64: 708-16.
42
Goodwin MD, Dobson JE, Sirlin CB, Lim BG, Stella DL. Diagnostic challenges and pitfalls in MR imaging with hepatocyte-specific contrast agents. Radiographics. 2011; 31: 1547-68.
43
Zech CJ, Grazioli L, Jonas E, Ekman M, Niebecker R, Gschwend S, et al. Health-economic evaluation of three imaging strategies in patients with suspected colorectal liver metastases: Gd-EOB-DTPA-enhanced MRI vs. extracellular contrast media-enhanced MRI and 3-phase MDCT in Germany, Italy and Sweden. Eur Radiol. 2009; 19 Suppl 3: S753-63.
44
Chen L, Zhang J, Zhang L, Bao J, Liu C, Xia Y, et al. Meta-analysis of gadoxetic acid disodium (Gd-EOB-DTPA)-enhanced magnetic resonance imaging for the detection of liver metastases. PLoS One. 2012; 7: e48681.
45
Brismar TB, Dahlstrom N, Edsborg N, Persson A, Smedby O, Albiin N. Liver vessel enhancement by Gd-BOPTA and Gd-EOB-DTPA: a comparison in healthy volunteers. Acta Radiol. 2009; 50: 709-15.
46
Haimerl M, Verloh N, Zeman F, Fellner C, Nickel D, Lang SA, et al. Gd-EOB-DTPA-enhanced MRI for evaluation of liver function: comparison between signal-intensity-based indices and T1 relaxometry. Sci Rep. 2017; 7: 43347.
47
Culverwell AD, Sheridan MB, Guthrie JA, Scarsbrook AF. Diffusion-weighted MRI of the liver-Interpretative pearls and pitfalls. Clin Radiol. 2013; 68: 406-14.
48
Galea N, Cantisani V, Taouli B. Liver lesion detection and characterization: role of diffusion-weighted imaging. J Magn Reson Imaging. 2013; 37: 1260-76.
49
Kim HJ, Lee SY, Shin YR, Park CS, Kim K. The value of diffusion-weighted imaging in the differential diagnosis of ovarian lesions: a meta-analysis. PLoS One. 2016; 11: e0149465.
50
Kwee TC, Takahara T, Ochiai R, Nievelstein RA, Luijten PR. Diffusion-weighted whole-body imaging with background body signal suppression (DWIBS): features and potential applications in oncology. Eur Radiol. 2008; 18: 1937-52.
51
Baghdadi A, Mirpour S, Ghadimi M, Motaghi M, Hazhirkarzar B, Pawlik TM, et al. Imaging of colorectal liver metastasis. J Gastrointest Surg. 2022; 26: 245-57.
52
Baliyan V, Das CJ, Sharma R, Gupta AK. Diffusion weighted imaging: technique and applications. World J Radiol. 2016; 8: 785-98.
53
Qayyum A. Diffusion-weighted imaging in the abdomen and pelvis: concepts and applications. Radiographics. 2009; 29: 1797-810.
54
Goshima S, Kanematsu M, Kondo H, Yokoyama R, Kajita K, Tsuge Y, et al. Diffusion-weighted imaging of the liver: optimizing b value for the detection and characterization of benign and malignant hepatic lesions. J Magn Reson Imaging. 2008; 28: 691-7.
55
Wu LM, Hu J, Gu HY, Hua J, Xu JR. Can diffusion-weighted magnetic resonance imaging (DW-MRI) alone be used as a reliable sequence for the preoperative detection and characterisation of hepatic metastases? A meta-analysis. Eur J Cancer. 2013; 49: 572-84.
56
Zech CJ, Reiser MF, Herrmann KA. Imaging of hepatocellular carcinoma by computed tomography and magnetic resonance imaging: state of the art. Dig Dis. 2009; 27: 114-24.
57
Vandecaveye V, De Keyzer F, Verslype C, Op de Beeck K, Komuta M, Topal B, et al. Diffusion-weighted MRI provides additional value to conventional dynamic contrast-enhanced MRI for detection of hepatocellular carcinoma. Eur Radiol. 2009; 19: 2456-66.
58
Bruegel M, Rummeny EJ. Hepatic metastases: use of diffusion-weighted echo-planar imaging. Abdom Imaging. 2010; 35: 454-61.
59
Feuerlein S, Pauls S, Juchems MS, Stuber T, Hoffmann MH, Brambs HJ, et al. Pitfalls in abdominal diffusion-weighted imaging: how predictive is restricted water diffusion for malignancy. AJR Am J Roentgenol. 2009; 193: 1070-6.
60
Sandrasegaran K, Akisik FM, Lin C, Tahir B, Rajan J, Aisen AM. The value of diffusion-weighted imaging in characterizing focal liver masses. Acad Radiol. 2009; 16: 1208-14.
61
Koh DM, Scurr E, Collins D, Kanber B, Norman A, Leach MO, et al. Predicting response of colorectal hepatic metastasis: value of pretreatment apparent diffusion coefficients. AJR Am J Roentgenol. 2007; 188: 1001-8.
62
Cui Y, Zhang XP, Sun YS, Tang L, Shen L. Apparent diffusion coefficient: potential imaging biomarker for prediction and early detection of response to chemotherapy in hepatic metastases. Radiology. 2008; 248: 894-900.
63
Venkatesh SK, Yin M, Ehman RL. Magnetic resonance elastography of liver: technique, analysis, and clinical applications. J Magn Reson Imaging. 2013; 37: 544-55.
64
Yin M, Glaser KJ, Talwalkar JA, Chen J, Manduca A, Ehman RL. Hepatic MR elastography: clinical performance in a series of 1377 consecutive examinations. Radiology. 2016; 278: 114-24.
65
Chi H, Hansen BE, Tang WY, Schouten JN, Sprengers D, Taimr P, et al. Multiple biopsy passes and the risk of complications of percutaneous liver biopsy. Eur J Gastroenterol Hepatol. 2017; 29: 36-41.
66
Singh S, Venkatesh SK, Wang Z, Miller FH, Motosugi U, Low RN, et al. Diagnostic performance of magnetic resonance elastography in staging liver fibrosis: a systematic review and meta-analysis of individual participant data. Clin Gastroenterol Hepatol. 2015; 13: 440-51.e6.
67
Tang A, Cloutier G, Szeverenyi NM, Sirlin CB. Ultrasound elastography and MR elastography for assessing liver fibrosis: part 1, principles and techniques. AJR Am J Roentgenol. 2015; 205: 22-32.
68
Chouhan MD, Lythgoe MF, Mookerjee RP, Taylor SA. Vascular assessment of liver disease-towards a new frontier in MRI. Br J Radiol. 2016; 89: 20150675.
69
Venkatesh SK, Yin M, Ehman RL. Magnetic resonance elastography of liver: clinical applications. J Comput Assist Tomogr. 2013; 37: 887-96.
70
Tokimori T, Saitoh S, Ohira S, Suzuki H, Kurita I, Tano M, et al. Quantitative equivalence of Quantitative Imaging Biomarkers Alliance (QIBA)-2023- and QIBA-2020-compliant MR elastography protocols for liver stiffness assessment. Abdom Radiol (NY). 2026.
71
Serai SD, Obuchowski NA, Venkatesh SK, Sirlin CB, Miller FH, Ashton E, et al. Repeatability of MR elastography of liver: a meta-analysis. Radiology. 2017; 285: 92-100.
72
Higuchi M, Tamaki N, Kurosaki M, Inada K, Kirino S, Yamashita K, et al. Changes of liver stiffness measured by magnetic resonance elastography during direct-acting antivirals treatment in patients with chronic hepatitis C. J Med Virol. 2021; 93: 3744-51.
73
Ferraioli G, Barr RG. Interpreting liver stiffness values in clinical practice: is histologic classification necessary for clinical relevance? Radiology. 2023; 307: e220553.
74
Chen J, Talwalkar JA, Yin M, Glaser KJ, Sanderson SO, Ehman RL. Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography. Radiology. 2011; 259: 749-56.
75
Takamura T, Motosugi U, Ichikawa S, Sano K, Morisaka H, Ichikawa T, et al. Usefulness of MR elastography for detecting clinical progression of cirrhosis from child-pugh class A to B in patients with type C viral hepatitis. J Magn Reson Imaging. 2016; 44: 715-22.
76
Gidener T, Dierkhising RA, Mara KC, Therneau TM, Venkatesh SK, Ehman RL, et al. Change in serial liver stiffness measurement by magnetic resonance elastography and outcomes in NAFLD. Hepatology. 2023; 77: 268-74.
77
Ajmera VH, Liu A, Singh S, Yachoa G, Ramey M, Bhargava M, et al. Clinical utility of an increase in magnetic resonance elastography in predicting fibrosis progression in nonalcoholic fatty liver disease. Hepatology. 2020; 71: 849-60.
78
Han MAT, Vipani A, Noureddin N, Ramirez K, Gornbein J, Saouaf R, et al. MR elastography-based liver fibrosis correlates with liver events in nonalcoholic fatty liver patients: a multicenter study. Liver Int. 2020; 40: 2242-51.
79
Tamaki N, Higuchi M, Kurosaki M, Kirino S, Osawa L, Watakabe K, et al. Risk assessment of hepatocellular carcinoma development by magnetic resonance elastography in chronic hepatitis C patients who achieved sustained virological responses by direct-acting antivirals. J Viral Hepat. 2019; 26: 893-9.
80
Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2015; 13: 643-54.e1-9; quiz e39-40.
81
Srinivasa Babu A, Wells ML, Teytelboym OM, Mackey JE, Miller FH, Yeh BM, et al. Elastography in chronic liver disease: modalities, techniques, limitations, and future directions. Radiographics. 2016; 36: 1987-2006.
82
Moura Cunha G, Fan B, Navin PJ, Olivié D, Venkatesh SK, Ehman RL, et al. Interpretation, reporting, and clinical applications of liver MR elastography. Radiology. 2024; 310: e231220.
83
Corradini E, Pietrangelo A. Iron and steatohepatitis. J Gastroenterol Hepatol. 2012; 27(Suppl 2): 42-6.
84
Welle CL, Olson MC, Reeder SB, Venkatesh SK. Magnetic resonance imaging of liver fibrosis, fat, and iron. Radiol Clin North Am. 2022; 60: 705-16.
85
Curtis WA, Fraum TJ, An H, Chen Y, Shetty AS, Fowler KJ. Quantitative MRI of diffuse liver disease: current applications and future directions. Radiology. 2019; 290: 23-30.
86
Moura Cunha G, Navin PJ, Fowler KJ, Venkatesh SK, Ehman RL, Sirlin CB. Quantitative magnetic resonance imaging for chronic liver disease. Br J Radiol. 2021; 94: 20201377.
87
Ajmera V, Loomba R. Imaging biomarkers of NAFLD, NASH, and fibrosis. Mol Metab. 2021; 50: 101167.
88
Low G, Ferguson C, Locas S, Tu W, Manolea F, Sam M, et al. Multiparametric MR assessment of liver fat, iron, and fibrosis: a concise overview of the liver “Triple Screen”. Abdom Radiol (NY). 2023; 48: 2060-73.
89
Roldan-Valadez E, Favila R, Martínez-López M, Uribe M, Ríos C, Méndez-Sánchez N. In vivo 3T spectroscopic quantification of liver fat content in nonalcoholic fatty liver disease: correlation with biochemical method and morphometry. J Hepatol. 2010; 53: 732-7.
90
van Werven JR, Schreuder TC, Aarts EO, Nederveen AJ, Meijer JW, Berends FJ, et al. Hepatic steatosis in morbidly obese patients undergoing gastric bypass surgery: assessment with open-system 1H-MR spectroscopy. AJR Am J Roentgenol. 2011; 19: W736-42.
91
Starekova J, Reeder SB. Liver fat quantification: where do we stand? Abdom Radiol (NY). 2020; 45: 3386-99.
92
Starekova J, Hernando D, Pickhardt PJ, Reeder SB. Quantification of liver fat content with CT and MRI: state of the art. Radiology. 2021; 301: 250-62.
93
Dyke JP. Quantitative MRI proton density fat fraction: a coming of age. Radiology. 2021; 29: 652-3.
94
Idilman IS, Keskin O, Celik A, Savas B, Elhan AH, Idilman R, et al. A comparison of liver fat content as determined by magnetic resonance imaging-proton density fat fraction and MRS versus liver histology in non-alcoholic fatty liver disease. Acta Radiol. 2016; 57: 271-8.
95
Kang BK, Kim M, Song SY, Jun DW, Jang K. Feasibility of modified Dixon MRI techniques for hepatic fat quantification in hepatic disorders: validation with MRS and histology. Br J Radiol. 2018; 91: 20170378.
96
Boudinaud C, Abergel A, Joubert-Zakeyh J, Fontarensky M, Pereira B, Chauveau B, et al. Quantification of steatosis in alcoholic and nonalcoholic fatty liver disease: evaluation of four MR techniques versus biopsy. Eur J Radiol. 2019; 118: 169-74.
97
Labranche R, Gilbert G, Cerny M, Vu KN, Soulières D, Olivié D, et al. Liver iron quantification with MR imaging: a primer for radiologists. Radiographics. 2018; 38: 392-412.
98
Low G, Huang G, Dharmana H, Moloo Z, Fu W. Re: PC Adams. Genetic testing for hemochromatosis: diagnostic or confirmatory test for iron overload? Can J Gastroenterol Hepatol. 2015; 29: 165-6.
99
Gandon Y, Olivié D, Guyader D, Aubé C, Oberti F, Sebille V, et al. Non-invasive assessment of hepatic iron stores by MRI. Lancet. 2004; 363: 357-62.
100
St Pierre TG, Clark PR, Chua-anusorn W, Fleming AJ, Jeffrey GP, Olynyk JK, et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood. 2005; 105: 855-61.
101
Wood JC, Enriquez C, Ghugre N, Tyzka JM, Carson S, Nelson MD, et al. MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood. 2005; 10: 1460-5.
102
Pavlides M, Banerjee R, Tunnicliffe EM, Kelly C, Collier J, Wang LM, et al. Multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease severity. Liver Int. 2017; 37: 1065-73.
103
Yoon JH, Lee JM, Paek M, Han JK, Choi BI. Quantitative assessment of hepatic function: modified look-locker inversion recovery (MOLLI) sequence for T1 mapping on Gd-EOB-DTPA-enhanced liver MR imaging. Eur Radiol. 2016; 26: 1775-82.
104
Kim JE, Kim HO, Bae K, Choi DS, Nickel D. T1 mapping for liver function evaluation in gadoxetic acid-enhanced MR imaging: comparison of look-locker inversion recovery and B 1 inhomogeneity-corrected variable flip angle method. Eur Radiol. 2019; 29: 3584-94.
105
Banerjee R, Pavlides M, Tunnicliffe EM, Piechnik SK, Sarania N, Philips R, et al. Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease. J Hepatol. 2014; 60: 69-77.
106
Bradley C, Scott RA, Cox E, Palaniyappan N, Thomson BJ, Ryder SD, et al. Short-term changes observed in multiparametric liver MRI following therapy with direct-acting antivirals in chronic hepatitis C virus patients. Eur Radiol. 2019; 29: 3100-7.
107
Janowski K, Shumbayawonda E, Dennis A, Kelly M, Bachtiar V, DeBrota D, et al. Multiparametric MRI as a noninvasive monitoring tool for children with autoimmune hepatitis. J Pediatr Gastroenterol Nutr. 2021; 72: 108-14.
108
Arndtz K, Shumbayawonda E, Hodson J, Eddowes PJ, Dennis A, Thomaides-Brears H, et al. Multiparametric magnetic resonance imaging, autoimmune hepatitis, and prediction of disease activity. Hepatol Commun. 2021; 5: 1009-20.
109
Kim JW, Lee YS, Park YS, Kim BH, Lee SY, Yeon JE, et al. Multiparametric MR index for the diagnosis of non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease. Sci Rep. 2020; 10: 2671.
110
Jabiyev A, Karçaaltıncaba M, Karaosmanoğlu AD, Akata D, Özmen MN, İdilman İS. Multiparametric magnetic resonance imaging, diffusion-weighted magnetic resonance imaging, and magnetic resonance elastography: differentiating benign and malignant liver lesions. Diagn Interv Radiol. 2026; 32: 133-8.
